Trials explorer

AI-generated summary

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing is being studied. Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer +7 • Eligibility: * INCLUSION CRITERIA: * Participants with a locally advanced or metastatic pathologically confirmed cancer whose NCI Licensed Independent Practitioner (LIP) determined they are candidates for treatment with atezolizumab,…. Goal: Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma is being studied. Conditions: Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma • Eligibility: Inclusion Criteria: 1. Male or female, aged ≥18 years, 2. Performance status Eastern Cooperative Oncology Group World Health Organization (ECOG-WHO) ≤1, 3. Histologically proven metastatic or locally advanced…. Goal: This study evaluates the feasibility of the combination of radiotherapy, chemotherapies (docetaxel, cisplatin and 5-fluorouracil) and spartalizumab (anti-PD-1 therapy) in patients with metastatic squamous cell anal carcinoma Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Hospitalier Universitaire de Besancon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors is being studied. Conditions: Solid Tumor, Adult, Lymphoma, EphA2 Overexpression +4 • Eligibility: Inclusion Criteria: 1. Age 18-75 (inclusive). 2. ECOG performance status ≤2 and Estimated life expectancy of more than 3 months. 3. Local advanced/metastatic solid tumors or R/R lymphomas…. Goal: This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide (TP53-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of TP53-EphA-2-CAR-DC vaccine; detect T cell response against TP53 mutant peptide and tumor neoepitopes after the treatment with TP53-EphA-2-CAR-DC vaccine and ICIs. Phase/Status/Sponsor: Unknown phase; RECRUITING; Chinese PLA General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AIO-BNHO CONNECT is a national, observational platform that collects and links patients’ clinical data with results from multi-gene NGS panels (more than 30 genes) for advanced solid tumors. It is for adults with locally advanced, inoperable, or metastatic tumors who have NGS data available; living patients must have provided informed consent, while data from deceased patients may be included. The aim is to learn how real-world genomic information relates to treatment outcomes and to map the current state of precision oncology in Germany across different care settings. There is also a decentralized tissue repository of annotated tumor samples to support future research. Exclusions include NSCLC, SCLC, and mesothelioma, and NGS results older than two years.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms is being studied. Conditions: Neuroendocrine (NE) Tumors, Endocrine Cancer • Eligibility: Inclusion Criteria: * Informed consent * Age ≥18 years * Histopathology confirmed endocrine neoplasm * Treatment with alkylating chemotherapy: Arm A; about to start alkylating chemotherapy, or Arm…. Goal: It has been showed that alkylating chemotherapy, particularly the widely used agent temozolomide, may cause high tumor mutational burden (TMB) in certain tumors by causing inactivating mutations in the DNA mismatch repair (MMR) system. This can cause therapy resistance and tumor progression but may also predict response for immunotherapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Uppsala University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a not-yet-recruiting, single-arm Phase II trial testing whether Sintilimab plus Bevacizumab and AG chemotherapy can be given as first-line treatment for adults with unresectable locally advanced or metastatic cholangiocarcinoma. The study is for adults aged 18–75 who have surgically unresectable disease, no prior systemic therapy (except some postoperative therapy more than 6 months ago), and at least one measurable lesion. It aims to learn how often tumors respond, how many patients have disease control, how long responses last, overall survival, and safety, and it will also explore biomarker signals like PD-L1 and tumor mutational burden. Key exclusions include prior anti-PD-1/PD-L1 therapy, active autoimmune disease needing systemic treatment, HIV, active HBV or HCV infection, pregnancy, high bleeding risk, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment is being studied. Conditions: Colorectal Cancer • Eligibility: Inclusion Criteria: 1. Have a full understanding of this study and voluntarily sign the informed consent form; 2. Aged 18 - 75 years; 3. Patients must be pathologically…. Goal: The goal of this clinical trial is to explore the preliminary efficacy and tolerability of Aipalolitovorelizumab (QL1706) in combination with fruquintinib for the treatment of metastatic colorectal cancer patients with immunodominant pMMR/MSS type who have failed second-line or above treatment. It is an open-label, single-arm, single-center phase II trial. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Harbin Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype is being studied. Conditions: Glioma, Glioblastoma, High Grade Glioma +2 • Eligibility: * INCLUSION CRITERIA: * Patients must have recurrent diffuse glioma (histologically confirmed by National Institutes of Health (NIH) Laboratory of Pathology) with isocitrate dehydrogenase 1 (IDH1) or isocitrate…. Goal: Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors is being studied. Conditions: Advanced Digestive System Tumor • Eligibility: Inclusion Criteria: * Age ≥18 years * Patients with unresectable locally advanced T3-4 stage or M1 stage metastatic digestive system tumors confirmed by histology or cytology, including gastric…. Goal: This is a prospective, open-label, exploratory, phase II basket clinical trial designed to evaluate the efficacy and safety of sintilimab in combination with pyrotinib with or without chemotherapy in patients with advanced HER2-positive digestive system malignancies. Eligible patients include those with locally advanced unresectable or metastatic gastric, colorectal, hepatocellular, biliary tract, or pancreatic cancers. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tongji Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients is being studied. Conditions: Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +2 • Eligibility: Inclusion Criteria: * Patient must be 18 to 75 years of age * Must have a confirmed diagnosis of Stage IIIB-D locally advanced or Stage IV melanoma (American…. Goal: This phase I/II trial tests the safety and side effects of LN-144 (Lifileucel) and pembrolizumab in treating patients with stage IIIB-D or stage IV melanoma that has spread to nearby tissue or lymph nodes. Biological therapies, such as LN-144 (Lifileucel), use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Richard Wu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types is being studied. Conditions: Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer +6 • Eligibility: Inclusion Criteria: * Subjects must have had at least one prior treatment with systemic therapy for advanced and unresectable, or metastatic disease OR is intolerant to, has refused…. Goal: Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Phase/Status/Sponsor: Unknown phase; SUSPENDED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.